High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and ewing’s sarcoma*

John Graham-Pole, Hillard M. Lazarus, Robert H. Herzig, Samuel Gross, Peter Coccia, Roy Weiner, Sarah Strandjord

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Neuroblastoma and Ewing’s sarcoma are examples of pediatric cancers in which disseminated disease is often present at diagnosis or develops later in spite of combina-tion therapy. The demonstration that marrow-ablative doses of chemotherapy can increase tumor cell kill, and that autologous bone marrow can be cryopreserved and reinfused into the patient to reverse such marrow ablation, has stimulated interest in this approach to refractory childhood cancers. We present results of treating eighteen patients with recurrent neuroblastoma and Ewing’s sarcoma resistant to conventional therapy. We used supralethal doses of melphalan, supported by reinfusion of previously cryo-preserved autologous bone marrow. Seven of 10 neuro-blastoma and six of eight Ewing’s sarcoma patients had complete or partial responses, lasting for a median of 6 months (neuroblastoma) and 3 months (Ewing’s sarcoma). Prolonged hospitalization, pancytopenia complicated by sepsis, and reversible gastrointestinal toxicity were the major side effects. These results suggest this approach should be tested in therapeutic trials at an earlier disease stage in children who have cancers with a predictably bad prognosis.

Original languageEnglish (US)
Pages (from-to)17-26
Number of pages10
JournalAmerican Journal of Pediatric Hematology/Oncology
Volume6
Issue number1
StatePublished - Jan 1 1984

Fingerprint

Ewing's Sarcoma
Melphalan
Neuroblastoma
Bone Marrow
Neoplasms
Pancytopenia
Therapeutics
Sepsis
Hospitalization
Pediatrics
Drug Therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Graham-Pole, J., Lazarus, H. M., Herzig, R. H., Gross, S., Coccia, P., Weiner, R., & Strandjord, S. (1984). High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and ewing’s sarcoma*. American Journal of Pediatric Hematology/Oncology, 6(1), 17-26.

High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and ewing’s sarcoma*. / Graham-Pole, John; Lazarus, Hillard M.; Herzig, Robert H.; Gross, Samuel; Coccia, Peter; Weiner, Roy; Strandjord, Sarah.

In: American Journal of Pediatric Hematology/Oncology, Vol. 6, No. 1, 01.01.1984, p. 17-26.

Research output: Contribution to journalArticle

Graham-Pole, J, Lazarus, HM, Herzig, RH, Gross, S, Coccia, P, Weiner, R & Strandjord, S 1984, 'High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and ewing’s sarcoma*', American Journal of Pediatric Hematology/Oncology, vol. 6, no. 1, pp. 17-26.
Graham-Pole, John ; Lazarus, Hillard M. ; Herzig, Robert H. ; Gross, Samuel ; Coccia, Peter ; Weiner, Roy ; Strandjord, Sarah. / High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and ewing’s sarcoma*. In: American Journal of Pediatric Hematology/Oncology. 1984 ; Vol. 6, No. 1. pp. 17-26.
@article{d63b8ef96b67484b9d96c5f2869e10e7,
title = "High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and ewing’s sarcoma*",
abstract = "Neuroblastoma and Ewing’s sarcoma are examples of pediatric cancers in which disseminated disease is often present at diagnosis or develops later in spite of combina-tion therapy. The demonstration that marrow-ablative doses of chemotherapy can increase tumor cell kill, and that autologous bone marrow can be cryopreserved and reinfused into the patient to reverse such marrow ablation, has stimulated interest in this approach to refractory childhood cancers. We present results of treating eighteen patients with recurrent neuroblastoma and Ewing’s sarcoma resistant to conventional therapy. We used supralethal doses of melphalan, supported by reinfusion of previously cryo-preserved autologous bone marrow. Seven of 10 neuro-blastoma and six of eight Ewing’s sarcoma patients had complete or partial responses, lasting for a median of 6 months (neuroblastoma) and 3 months (Ewing’s sarcoma). Prolonged hospitalization, pancytopenia complicated by sepsis, and reversible gastrointestinal toxicity were the major side effects. These results suggest this approach should be tested in therapeutic trials at an earlier disease stage in children who have cancers with a predictably bad prognosis.",
author = "John Graham-Pole and Lazarus, {Hillard M.} and Herzig, {Robert H.} and Samuel Gross and Peter Coccia and Roy Weiner and Sarah Strandjord",
year = "1984",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "17--26",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and ewing’s sarcoma*

AU - Graham-Pole, John

AU - Lazarus, Hillard M.

AU - Herzig, Robert H.

AU - Gross, Samuel

AU - Coccia, Peter

AU - Weiner, Roy

AU - Strandjord, Sarah

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Neuroblastoma and Ewing’s sarcoma are examples of pediatric cancers in which disseminated disease is often present at diagnosis or develops later in spite of combina-tion therapy. The demonstration that marrow-ablative doses of chemotherapy can increase tumor cell kill, and that autologous bone marrow can be cryopreserved and reinfused into the patient to reverse such marrow ablation, has stimulated interest in this approach to refractory childhood cancers. We present results of treating eighteen patients with recurrent neuroblastoma and Ewing’s sarcoma resistant to conventional therapy. We used supralethal doses of melphalan, supported by reinfusion of previously cryo-preserved autologous bone marrow. Seven of 10 neuro-blastoma and six of eight Ewing’s sarcoma patients had complete or partial responses, lasting for a median of 6 months (neuroblastoma) and 3 months (Ewing’s sarcoma). Prolonged hospitalization, pancytopenia complicated by sepsis, and reversible gastrointestinal toxicity were the major side effects. These results suggest this approach should be tested in therapeutic trials at an earlier disease stage in children who have cancers with a predictably bad prognosis.

AB - Neuroblastoma and Ewing’s sarcoma are examples of pediatric cancers in which disseminated disease is often present at diagnosis or develops later in spite of combina-tion therapy. The demonstration that marrow-ablative doses of chemotherapy can increase tumor cell kill, and that autologous bone marrow can be cryopreserved and reinfused into the patient to reverse such marrow ablation, has stimulated interest in this approach to refractory childhood cancers. We present results of treating eighteen patients with recurrent neuroblastoma and Ewing’s sarcoma resistant to conventional therapy. We used supralethal doses of melphalan, supported by reinfusion of previously cryo-preserved autologous bone marrow. Seven of 10 neuro-blastoma and six of eight Ewing’s sarcoma patients had complete or partial responses, lasting for a median of 6 months (neuroblastoma) and 3 months (Ewing’s sarcoma). Prolonged hospitalization, pancytopenia complicated by sepsis, and reversible gastrointestinal toxicity were the major side effects. These results suggest this approach should be tested in therapeutic trials at an earlier disease stage in children who have cancers with a predictably bad prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0021166233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021166233&partnerID=8YFLogxK

M3 - Article

C2 - 6370012

AN - SCOPUS:0021166233

VL - 6

SP - 17

EP - 26

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 1

ER -